Buy Ipamorelin Canada | GH Secretagogue 10mg
Janoshik
Batch IPAM-CA-26G-10
Buy Ipamorelin Canada | GH Secretagogue 10mg
Ghrelin Receptor Research Peptide
Ipamorelin is a selective growth hormone secretagogue studied in laboratory settings for its ability to stimulate GH release through ghrelin receptor pathways. Research often explores its effects on recovery-related signaling, protein metabolism, and regulation of growth hormone dynamics in controlled experimental models.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
Ipamorelin is a synthetic peptide developed for controlled laboratory research involving ghrelin receptor signaling systems. It is structurally designed to interact with growth hormone secretagogue receptor (GHS-R1a) pathways within experimental environments.
In scientific literature, ipamorelin is studied in models examining receptor-mediated signaling cascades, endocrine pathway interaction, and downstream cellular response systems under in vitro and preclinical research conditions.
Third-party tested for purity, ID, quantity.
Ipamorelin is a selective synthetic growth hormone secretagogue evaluated in research focused on ghrelin receptor activity and endocrine signaling pathways. Experimental studies examine receptor interaction models, hypothalamic-pituitary signaling systems, and regulated peptide response mechanisms.
Preclinical research publications have explored its receptor-binding characteristics and downstream signaling behavior within controlled laboratory environments.
Ipamorelin was developed during research efforts investigating selective growth hormone secretagogues with targeted receptor interaction. Studies explored its specificity toward ghrelin receptor pathways and its role within endocrine signaling research frameworks.
Subsequent experimental work documented its receptor interaction profile and signaling characteristics in laboratory models.
Laboratory investigations into ipamorelin have focused on ghrelin receptor activation models and endocrine-related signaling pathways. Research frameworks evaluate receptor-mediated interaction, peptide specificity, and downstream regulatory mechanisms under controlled in vitro and preclinical conditions.
2 of the 4 areas below are addressed directly by a paper cited on this page.
Ghrelin receptor activation models
No paper cited on this page reports on ghrelin, receptor or activation. This heading marks where Ipamorelin is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Growth hormone secretagogue pathway studies
Addressed on this page by Raun 1998, Johansen 1999, Gobburu 1999. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Raun, K. et al. (1998) — Ipamorelin, the first selective growth hormone secretagogue.
- Johansen, P.B. et al. (1999) — Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.
- Gobburu, J.V.S. et al. (1999) — Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.
Endocrine signaling research frameworks
No paper cited on this page reports on endocrine. This heading marks where Ipamorelin is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Receptor-selective peptide interaction investigations
Addressed on this page by Raun 1998, Johansen 1999, Gobburu 1999. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Raun, K. et al. (1998) — Ipamorelin, the first selective growth hormone secretagogue.
- Johansen, P.B. et al. (1999) — Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.
- Gobburu, J.V.S. et al. (1999) — Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.
The references section of this page cites 3 primary papers published between 1998 and 1999 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Ipamorelin, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Ipamorelin is also referred to as ipa.
Ipamorelin is commonly described online in connection with muscle growth, fat loss and improved recovery. In the research literature the same compound is filed under ghrelin receptor activation models, growth hormone secretagogue pathway studies and endocrine signaling research frameworks.
Of the 3 papers cited on this page, published between 1998 and 1999, 1 reports work in human participants — Gobburu 1999. Human data for a molecule is not the same as evidence for material supplied as a research compound: published trials use pharmaceutical-grade product under medical supervision at defined doses. What is established for the material sold here is its measured purity and content per lot.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for Ipamorelin is per lot, not per product. The current 10mg lot IPAM-CA-26G-10 returned 99.753% purity, 11.75 mg measured, 117.5% of the labelled 10 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is Ipamorelin; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for Ipamorelin, this lot measured 117.5% of its labelled 10 mg. Both numbers are published for every lot, whichever way they fall.
The lot code printed on the vial matches the code on the certificate for Ipamorelin. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy Ipamorelin in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Bacteriostatic water in most published protocols
- Format
- Lyophilized powder
Ipamorelin is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 5 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial in the strength selected (10mg / Single Vial, 10mg / 5-Pack, 10mg / 10-Pack available), batch-labelled
- The batch-linked Certificate of Analysis for the exact lot shipped
- Discreet outer packaging with no product names on the exterior
- Canada Post Xpress, tracked, typically 1–2 business days from Alberta
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains 10mg of lyophilized ipamorelin. Independent third-party testing verifies purity, identity, and net content per batch.
The vial contains only the lyophilized peptide. Any laboratory materials required for experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
Related
You May Also Like
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
$60.00
$70.00
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
$35.00
$40.00
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$70.00
This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
$150.00